Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer

Active:	Yes
Cancer Type:	Prostate Cancer	NCT ID:	NCT04848337
Trial Phases:	Phase II	Protocol IDs:	HCRN GU19-385 (primary) NCI-2021-06868
Eligibility:	18 Years and older, Male	Study Type:	Treatment
Study Sponsor:	University of Michigan Rogel Cancer Center
NCI Full Details:	http://clinicaltrials.gov/show/NCT04848337

Summary

Eligible patients will be treated with the combination of lenvatinib and pembrolizumab. A
cycle equals 21 days and therapy will continue until radiographic progression,
intolerable toxicity, or patient/physician wishes to discontinue protocol therapy. A
maximum of 35 cycles may be administered. On Day 1, when both pembrolizumab and
lenvatinib are administered, patients should take the lenvatinib per their normal
routine.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.